Navigation Links
Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Date:12/9/2012

roduce and store extra blood cells, which can cause these organs to become enlarged.

Most patients with MF have greatly enlarged spleens (splenomegaly) that can result in a range of vague symptoms with dramatic impact on quality of life.  These include fatigue, abdominal pain, night sweats, feeling full without eating, cough or shortness of breath and decreased physical activity. Other signs and symptoms of MF include anemia, thrombocytopenia, weight loss and severe itching.

The exact prevalence of MF is not known.  The latest research estimates that the prevalence of MF ranges from 4.2 to 5.6 per 100,000 people in the U.S., or approximately 15,000 patients.  Prevalence estimates in Europe are less clear.  People over age sixty are most likely to develop this disease, with men and women equally at risk.

About JAK2 and SAR302503
JAK2 is a key enzyme for blood cell development. Mutations in JAK2 can lead to dysregulated JAK2 signaling and are thought to be a cause of MF.  Patients with wild type JAK2 have also been shown to have persistent, dysregulated activation of the JAK2 signaling pathway.

SAR302503 is a novel, investigational, selective inhibitor of the JAK/STAT signaling pathway that preferentially inhibits JAK2.  Sanofi Oncology is developing the compound for the treatment of the three main types of myeloproliferative neoplasms: primary myelofibrosis, polycythemia vera and essential thrombocythemia. Sanofi is also studying the effect of the compound on reducing/reversing scarring in the bone marrow. 

About Sanofi Oncology
Based in Cambridge, Massachusetts, USA and Vitry, France, Sanofi Oncology is dedicated to translating science into effective therapeutics that address unmet medical needs for cancer and organ transplant patients. Starting with a deep understanding of the disease and the patient, Sanofi Oncology employs innovative approaches to drug discovery and clinic
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 RnRMarketResearch.com ... therapeutic market research report of 52 pages with ... business intelligence library. The report "Visceral ... the therapeutic development for Visceral Pain, complete with ... drug target, mechanism of action (MoA), route of ...
(Date:3/27/2015)... YORK , March 27, 2015 /PRNewswire/ ... the leading source of health information, today ... the new National Action Plan for ... President Obama emphasized the urgency and importance ... on national and global health.    ...
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
Breaking Medicine Technology:Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
(Date:3/27/2015)... Canadian Cannabis Clinics ( http://www.cannabisclinics.ca ), ... of medical cannabis as a treatment for patients ... clinics dedicated to providing access to safe medical ... patients searching for medical marijuana treatment in legal ... sub domain for Canada. , With the ...
(Date:3/27/2015)... The Florida Center for Brain Tumor ... (ABC2), awarded $350,000 to support brain cancer research at ... Research Institute and H. Lee Moffitt Cancer Center and ... clear development path and potential to provide meaningful improvements ... , The awards fund research in areas on ...
(Date:3/26/2015)... Let’s not lose focus of why ... today’s traffic magnets. Three out of 4 consumers choose ... produce department, according to a Packaged Facts survey. Produce ... looking to add more fruits and vegetables to their ... is April 2. As featured in the Chase’s Calendar ...
(Date:3/26/2015)... The American College of Traditional Chinese Medicine announces several ... DAOM Program as well as Marketing Basics for Healers & ... by Dr. Carla Wilson, who will give an overview of ... prepare for the spring quarter. The webinar will be from ... and April 3. Attendees can log in from work or ...
(Date:3/26/2015)... Building off their success and ... the Cardiometabolic Risk Summit and ... are proud to announce a pioneering professional ... interdisciplinary program , which ultimately grants a Certified ... physicians, nurse practitioners, physician assistants, registered dietitians, and ...
Breaking Medicine News(10 mins):Health News:Canadian Cannabis Clinics (CCC) to Join the Canada.MarijuanaDoctors.com Network 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 3Health News:ACTCM Announces Upcoming Webinars 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3
... A study finds that sleep deprivation can adversely affect ... the expectation of gains and making light of ... understand the neural underpinnings of risky decision making under ... Duke University studied healthy volunteers as they underwent functional ...
... older women - those 80 or older - have the greatest ... today. ,Worryingly, the research also found that 56 per ... cancer risk. ,The strongest risk factor for breast cancer ... her risk. About one in 70 women will develop breast cancer ...
... risk of cancer; a Danish study conducted amongst 28,000 ... ,Danish medical records were analyzed to monitor ... among the utility workers for 23years. This was done ... and its effects. ,The researchers did not ...
... definite link between pregnancy, migraine and stroke, US researchers ... one. ,In fact, Cheryl Bushnell, assistant professor ... Disease in Durham, explained that pregnant women who suffered ... than pregnant women who did not suffer migraine. ...
... talked about testosterone cream for enhancing sexual desire in female ... conducted by Mayo clinic has shown. ... As an extension to a previous study which pointed a ... with sufficient estrogen levels, this new study was conducted on ...
... one out of depression. But its potential to drive ... ,Now the U.S. Food and Drug Administration (FDA) ... the existing black box warning on their products' labeling ... and behavior, in young adults ages 18 to 24 ...
Cached Medicine News:Health News:Sleep Deprivation can Affect Competent Decision-making 2Health News:Women Unaware of When Breast Cancer Risk is Greatest 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3
... is a premium agarose used for isolating ... agarose produces clear sharp bands, with no ... of UltraClean Forensic Agarose is tested and ... RNase activity and DNA contamination. ...
... is specifically formulated for high resolution of ... bp. This standard melting temperature agarose can ... 10 bp difference in size. UltraPure™ ... structure for better handling and improved clarity ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... solid. Highly purified non-ionic fraction of agar. ... very low concentrations. Can be mounted on ... films are elastic and durable and show ... either protein or lipoprotein dyes. Contaminants: ...
Medicine Products: